Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Neuropeptides. 2015 Sep 25;55:127–135. doi: 10.1016/j.npep.2015.09.006

Figure 2. NPY levels in normal pregnancies and preeclampsia.

Figure 2

A) NPY immunoreactivity (NPY-ir) measured by radioimmunoassay in platelet rich plasma (PRP) of subjects with normal pregnancies (NP) and preeclampsia (PE). B) NPY-ir per 100,000 platelets in NP and PE. C) NPY-ir measured in platelet poor plasma (PPP) of subjects with NP and PE. D) NPY-ir in PRP of patients with NP or PE subdivided into placental PE (PLPE) and maternal PE (MTPE) groups. E) NPY-ir per 100,000 platelets in NP, PLPE and MTPE groups. F) NPY-ir in PPP of subjects with NP, PLPE and MTPE. G) NPY-ir in sera of subjects with NP and PE, H) Serum NPY-ir levels in NP, PLPE and MTPE. ** - p<0.01 and * - p<0.05, as compared to NP; # -p<0.05, as compared to PLPE.